Novavax (NVAX) Reports Q2, Issues Operational Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Novavax (NVAX) shares tumble as Q2 results miss estimates, guidance cut
August 8, 2024 8:57 AM EDTNovavax (NASDAQ: NVAX) shares plunged 13.8% premarket Thursday after the vaccine maker reported second-quarter results that missed analyst expectations and lowered its full-year revenue guidance.
The company posted adjusted earnings per share of $0.99, falling short of the $1.67 consensus estimate. Revenue came in at $415 million, below the $464.83 million analysts were expecting and down slightly from... More
